Navigation Links
Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
Date:8/4/2008

EMERYVILLE, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received a quarterly royalty payment of approximately $2.1 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of moderate-to-severe Alzheimer's disease. Under an exclusive marketing agreement, NTI currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in phase 3 clinical testing as a novel investigational drug for treating acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to double the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI's pipeline also includes a phase 3 investigational drug for brain swelling and other drug candidates in early-stage development for Alzheimer's and Huntington's diseases.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies CEO to Retire on December 31, 2008
2. Neurobiological Technologies Reports Third Quarter Financial Results
3. Neurobiological Technologies Sets Date for Third Quarter Financial Results
4. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
5. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
8. Neurobiological Technologies Sets Date for Research and Development Day
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
11. Neurobiological Technologies Sets Date for Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... ... is now being assessed in clinical trials in the United States. (clinicaltrials.gov : ... your nurse or physician or find your nearest participating clinic here https://factor-therapeutics.com/clinical-trials/ ...
(Date:9/21/2017)... , ... September 21, 2017 , ... Dr. Greg Leyer, ... Vegas, NV on September 27th. His presentation is at 12:10pm in the Probiotics Resource ... to present at SupplySide West and discuss how probiotics have shown impressive data in ...
(Date:9/21/2017)... ... September 21, 2017 , ... Colpitts Clinical has launched the ... includes new features that facilitate streamlined and compliant communication, file sharing and document ... forefront of medical advancements, they rely on efficiencies to help them address the ...
(Date:9/21/2017)... New Jersey (PRWEB) , ... September 21, 2017 ... ... highly-regulated pharmaceutical and clinical research sector professionals, has announced the addition of 5 ... Part 11 training - Compliance with Regulation 21 CFR Part 11 on ...
Breaking Biology Technology:
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
Breaking Biology News(10 mins):